Filing Flows › Mesa Laboratories (MLAB) › Stock forecast & fair value
Mesa Laboratories (MLAB) stock forecast and fair value
Mesa Laboratories (MLAB) trades at $128.07. One analyst's price target is $125.00 (-2%). Across 26 valuation methods the middle fair value is $29.41 (-77%); the DCF says $26.99.
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| Regime-switching Monte Carlo 10th–90th | −$28.31 | $34.13 | $125.55 | -73% |
| DCF — Monte Carlo 10th–90th percentile | −$30.40 | $26.99 | $76.88 | -79% |
| P/E vs peers | $18.24 | $26.42 | $31.00 | -79% |
| P/E vs peers, weighted | $24.14 | $29.41 | $34.62 | -77% |
| P/E vs peers, matched | $19.31 | $25.85 | $40.71 | -80% |
| EV/EBITDA vs peers | $72.19 | $86.43 | $110.84 | -33% |
| EV/EBITDA vs peers, weighted | $76.31 | $95.56 | $111.63 | -25% |
| EV/EBITDA vs peers, matched | $67.06 | $84.22 | $114.45 | -34% |
| EV/Sales vs peers | $153.81 | $280.96 | $304.77 | +119% |
| EV/Sales vs peers, weighted | $223.82 | $280.17 | $309.95 | +119% |
Mesa Laboratories' latest quarter
Mesa Laboratories, Q1 FY27: revenue $60.1M (+1% year over year), operating margin 11.7%, net earnings $2.8M, operating cash flow $14.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for MLAB stock?
One analyst's 12-month target is $125.00, -2% from $128.07. The average rating is none.
What is Mesa Laboratories' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $4.17 and $280.96, with a middle value of $29.41 against a price of $128.07. Each method's assumptions are on the page.
Does Mesa Laboratories usually beat earnings estimates?
It beat the consensus EPS estimate in 75% of the quarters on record.
Is MLAB stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.